Author(s):
Contreras, Marinela ; Vicente, Joaquín ; Cerón, José Joaquín ; Martinez Subiela, Silvia ; Urra, José Miguel ; Rodríguez-del-Río, Francisco J. ; Ferreras-Colino, Elisa ; Vaz-Rodrigues, Rita ; de Fernández de Mera, Isabel G. ; Antunes, Sandra ; Domingos, Ana ; Gortázar, Christian ; de la Fuente, José
Date: 2023
Persistent ID: http://hdl.handle.net/10362/154354
Origin: Repositório Institucional da UNL
Subject(s): antibody isotype; epitope mapping; prognostic, SARS-CoV-2; spike protein; RA0421 Public health. Hygiene. Preventive Medicine; QR355 Virology; QR Microbiology; QR180 Immunology; Infectious Diseases; Immunology and Allergy; Immunology; SDG 3 - Good Health and Well-being; SDG 9 - Industry, Innovation, and Infrastructure
Description
Funding Information: This study was supported by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación, Spain and EU‐FEDER [Grant BIOGAL PID2020‐116761GB‐I00]. M.C. was funded by the Ministerio de Ciencia, Innovación y Universidades, Spain, grant IJC2020‐042710‐I. RV‐R was funded by Universidad de Castilla‐La Mancha (UCLM), Spain and the European Social Fund (ESF) [grant 2022‐PRED‐20675]. Funding Information: This study was supported by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación, Spain and EU-FEDER [Grant BIOGAL PID2020-116761GB-I00]. M.C. was funded by the Ministerio de Ciencia, Innovación y Universidades, Spain, grant IJC2020-042710-I. RV-R was funded by Universidad de Castilla-La Mancha (UCLM), Spain and the European Social Fund (ESF) [grant 2022-PRED-20675]. Publisher Copyright: © 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still poses a challenge for biomedicine and public health. To advance the development of effective diagnostic, prognostic, and preventive interventions, our study focused on high-throughput antibody binding epitope mapping of the SARS-CoV-2 spike RBD protein by IgA, IgM and IgG antibodies in saliva and sera of different cohorts from healthy uninfected individuals to SARS-CoV-2-infected unvaccinated and vaccinated asymptomatic, recovered, nonsevere, and severe patients. Identified candidate diagnostic (455-LFRKSNLKPFERD-467), prognostic (395-VYADSFVIRGDEV-407-C-KLH, 332-ITNLCPFGEV-342-C-KLH, 352-AWNRKRI-358-C-KLH, 524-VCGPKKSTNLVKN-536-KLH), and protective (MKLLE-487-NCYFPLQSYGFQPTNGVG-504-GGGGS-446-GGNYNYLYRLFRKSNLKPFERD-467) epitopes were validated with sera from prevaccine and postvaccine cohorts. The results identified neutralizing epitopes and support that antibody recognition of linear B-cell epitopes in RBD protein is associated with antibody isotype and disease symptomatology. The findings in asymptomatic individuals suggest a role for anti-RBD antibodies in the protective response against SARS-CoV-2. The possibility of translating results into diagnostic interventions for the early diagnosis of asymptomatic individuals and prognosis of disease severity provides new tools for COVID-19 surveillance and evaluation of risks in hospitalized patients. These results, together with other approaches, may contribute to the development of new vaccines for the control of COVID-19 and other coronavirus-related diseases using a quantum vaccinomics approach through the combination of protective epitopes.
